News & Updates

Once-weekly injection of tirzepatide, a dual GIP and GLP-1 receptor antagonist, slowed eGFR* decline and reduced UACR** in patients with type 2 diabetes (T2D) who are at high risk of cardiovascular (CV) disease compared with once-daily insulin glargine (iGlar), according to a prespecified post hoc analysis of the SURPASS-4*** trial presented at EASD 2022.

Use of aspirin offers health benefits to older individuals with elevated lipoprotein(a) genotypes by preventing cardiovascular events, suggests a study.

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

Utilization of hearts donated after circulatory death (DCD) appears to result in transient post-transplant right heart dysfunction and short-term clinical outcomes otherwise comparable to transplantation using hearts donated after brain death (DBD), reveals a recent study.

Reproductive factors such as irregular menstrual cycles, nulliparity, and multiparity contribute to an increased risk of new-onset atrial fibrillation in women, as reported in a study.

Among older adults suffering from hip fractures, calf deep vein thrombosis (DVT) appears to significantly aggravate the risk of 30-day all-cause mortality, a recent study has found. However, no such effect exists for the 90-day death risk.